OSE Pharma s’introduit sur Euronext Paris


Raises €21.1 million, market capitalisation totals €108 million

Paris – 30 March 2015– EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs[1],today congratulatedOSE Pharma, a biotechnology company based in France that is developing immunotherapy treatments for invasive/metastatic late-stage cancers, on its successful listing in Compartment C of Euronext’s regulated market in Paris.

Paris-based OSE Pharma was founded in 2012 by Dominique Costantini and Emile Loria, two experienced entrepreneurs specialising in biotechnology. The company is developing an innovative cancer immunotherapy solution called Tedopi® — a patented combination therapy now entering a Phase 3 study for patients with advanced non-small cell lung cancer (NSCLC). In Europe, Tedopi® is considered as personalised medicine in a population of treatment-responsive patients; in the USA, it has been granted orphan drug status and thus qualifies for accelerated clinical development.

OSE Pharma (ticker symbol: OSE) was listed through the admission to trading of 9,980,947 ordinary shares making up its equity, including 1,955,000 new shares issued under a Global Offering[2] after full exercise of the extension clause and before possible exercise of the over-allotment option.

The admission and issue price of OSE Pharma was set at €10.80 euros per share, at the high end of the price range. Market capitalisation on the day of listing was €108 million, and the operation raised a total of €21.1 million.

Dominique Costantini, OSE Pharma’s CEO and co-founder, said:“We are proud to have convinced French and European investors to join forces and support us, and we wish to thank them. The cost of our pivotal clinical phase III study of Tedopi® is now fully covered and we are looking into a new exploratory phase II study (in therapeutic combination or for new indications against other cancers). At this point, we have the resources we need to pursue our clinical studies for the next three years, to bring a new therapeutic solution to patients — and to start actively seeking pharmaceutical partners to promote our technology and our product.”

Eric Forest, Chairman and CEO of EnterNext, said: “We are delighted to welcome OSE Pharma to Euronext in Paris. This is the fourth biotech company to list on Euronext since January this year, making us the European benchmark for life-science businesses seeking capital. OSE Pharma’s listing will raise its profile with investors and give it access to promotional input and other assistance from EnterNext.”

[1]Small and medium-size companies
The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries


Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2023, Euronext N.V. - All rights reserved.